Please try another search
For the three months ended 31 March 2022, Samsung Pharm Co Ltd revenues decreased 8% to W12.58B. Net loss decreased 89% to W1.5B. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Interest Expense decrease of 93% to W27.8M (expense), Salaries & Wages decrease of 28% to W866.9M (expense).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 12582.64 | 14034.82 | 10449.95 | 16806.61 |
Gross Profit | 8021.63 | 515.68 | 501.04 | 3659.93 |
Operating Income | -406.81 | -9713.11 | -5416.79 | -2838.86 |
Net Income | -1499.96 | -13308.08 | -6708.73 | -6263.55 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 137810.94 | 145456.08 | 155196.23 | 162646.49 |
Total Liabilities | 12040.43 | 18185.6 | 14685.33 | 15426.87 |
Total Equity | 125770.51 | 127270.47 | 140510.89 | 147219.62 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -147.12 | -7162.79 | -6141.63 | -1246.33 |
Cash From Investing Activities | 4467.88 | 18985.31 | 3034.83 | 40229.75 |
Cash From Financing Activities | -215.49 | -12211.64 | -11787.92 | -11752.58 |
Net Change in Cash | 4110.94 | -347.39 | -14867.65 | 27242.71 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review